Holen Sie sich die Stockscreener-App
481.16
0.19%
0.66
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation - ChartMill
Vertex Pharma stock trades near record levels as cystic fibrosis franchise drives earnings growth - Ad-hoc-news.de
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating - Moomoo
Vertex Pharma stock trades near highs as cystic fibrosis portfolio drives double digit revenue growt - Ad-hoc-news.de
Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals - BioSpace
How FDA’s Pediatric Expansion of Casgevy at Vertex Pharmaceuticals (VRTX) Has Changed Its Investment Story - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Wins FDA Nod To Treat Children As Young As 2 - Yahoo Finance Singapore
Vertex Pharmaceuticals just made a $10 billion acquisition worth watching - MSN
Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching - The Motley Fool
Latigo preps IPO to fund non-opioid rival to Vertex’s Journax - Fierce Biotech
Vertex Pharma stock steadies as cystic fibrosis franchise drives revenue and investors watch next da - ad-hoc-news.de
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
5 Best Biotech Stocks for 2026 and How to Invest - The Motley Fool
Parkinson’s in the Clinic, Insilico enters Phase III, Vertex Acquires Crinetics - genengnews.com
Vertex Pharma stock trades near record highs as cystic fibrosis franchise drives earnings momentum - Ad Hoc News
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Lobbying Update: $1,200,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Quiver Quantitative
Is Vertex Pharmaceuticals Successfully Diversifying Beyond Cystic Fibrosis - Kavout | AI
Vertex Pharmaceuticals Inc Stock Price Live, Charts & News - The Economic Times
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vertex Pharma stock steadies as analysts watch cystic fibrosis - ad-hoc-news.de
Vertex Pharmaceuticals (Ondo Tokenized) price today, VRTXON to USD live price, marketcap and chart - CoinDesk
Vertex Pharmaceuticals Currently Down Seven Consecutive Days, on Pace for Longest Losing Streak Since August 2021 -- Data Talk - Moomoo
Vertex Pharmaceuticals Stock 6-Day Losing Spree: Stock Falls 10% - Trefis
Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal - Yahoo Finance
Vertex Pharmaceuticals Stock Slides 10% Over 6 Straight Down Days - Trefis
Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal - simplywall.st
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Calamos Advisors LLC - InsuranceNewsNet
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $550 to $600 - Moomoo
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals - AOL.com
Analysts Conflicted on These Healthcare Names: Exelixis (EXEL) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? - The Motley Fool
VRTX Maintained by UBS -- Price Target Raised to $585 - GuruFocus
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? - The Motley Fool
UBS Adjusts Vertex Pharmaceuticals Price Target to $585 From $545, Maintains Buy Rating - Moomoo
VRTX Maintained by Truist Securities -- Price Target Raised to $560 - GuruFocus
What to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings Report - Yahoo Finance
Truist raises Vertex stock price target to $560 on Crinetics deal - Investing.com
Wells Fargo Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $550 - Moomoo
Vertex Pharma stock holds steady as cystic fibrosis franchise underpins long-term growth outlook - ad-hoc-news.de
Drugmaker Vertex spends $10B to buy biotech firm to expand rare-disease offerings - Post and Courier
Vertex Pharmaceuticals (VRTX) Announces $10B Acquisition of Crin - GuruFocus
Vertex Pharmaceuticals (VRTX) Announces $10B Acquisition of Crinetics Pharmaceuticals - GuruFocus
The week in pharma: action, reaction and insight – week to July 10, 2026 - The Pharma Letter
Vertex (VRTX) Wins FDA Expansion For CASGEVY And Advances ALYFTREK In Canada - Yahoo Finance
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse - TradingView
Biotech Stocks Face Big $15B Hit as Vertex, Ionis Skew Flat Weekly Tape - TechStock²
Is This Biotech Stock a Buy Near Its 52-Week High? - The Motley Fool
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Crinetics Pharmaceuticals (CRNX) sets 1-year executive non-competes tied to Vertex deal - Stock Titan
Why This Pharmaceutical Stock Jumped Close to 100% This Week - Yahoo Finance
Weekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal - RTTNews
Nvidia, Vertex Pharmaceuticals And More On CNBC’s ‘Final Trades’ - Sahm
Rx Rundown: Vertex Pharmaceuticals, Real Chemistry, Vera Therapeutics and more - Medical Marketing and Media
A $10B deal, China trial scrutiny and highlights from ADA 2026 - Fierce Pharma
If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
0.40%
1.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):